Immortalization Reversibility in the Context of Cell Therapy Biosafety

Immortalization (genetically induced prevention of replicative senescence) is a promising approach to obtain cellular material for cell therapy or for bio-artificial organs aimed at overcoming the problem of donor material shortage. Immortalization is reversed before cells are used in vivo to allow...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-04, Vol.24 (9), p.7738
Main Authors: Sutyagina, Oksana I, Beilin, Arkadii K, Vorotelyak, Ekaterina A, Vasiliev, Andrey V
Format: Article
Language:English
Subjects:
Artificial chromosomes
Artificial organs
Biological products
Biosafety
Cell cycle
Cell Differentiation
Cell division
Cell Line
Cell lines
Cell Proliferation
Cell therapy
Containment of Biohazards
CRISPR
Differentiation (biology)
Donor materials
Extracellular matrix
Genotype & phenotype
Human papillomavirus
Immortalization
Insulin
Liu, Timothy
Phenotypes
Proteins
Recombination
Review
Safety and security measures
Senescence
Stem cells
Suicide
Suicide genes
Telomerase
Telomerase - metabolism
Tetracycline
Tetracyclines
Tissue engineering
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3
cites cdi_FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3
container_end_page
container_issue 9
container_start_page 7738
container_title International journal of molecular sciences
container_volume 24
creator Sutyagina, Oksana I
Beilin, Arkadii K
Vorotelyak, Ekaterina A
Vasiliev, Andrey V
description Immortalization (genetically induced prevention of replicative senescence) is a promising approach to obtain cellular material for cell therapy or for bio-artificial organs aimed at overcoming the problem of donor material shortage. Immortalization is reversed before cells are used in vivo to allow cell differentiation into the mature phenotype and avoid tumorigenic effects of unlimited cell proliferation. However, there is no certainty that the process of de-immortalization is 100% effective and that it does not cause unwanted changes in the cell. In this review, we discuss various approaches to reversible immortalization, emphasizing their advantages and disadvantages in terms of biosafety. We describe the most promising approaches in improving the biosafety of reversibly immortalized cells: CRISPR/Cas9-mediated immortogene insertion, tamoxifen-mediated self-recombination, tools for selection of successfully immortalized cells, using a decellularized extracellular matrix, and ensuring post-transplant safety with the use of suicide genes. The last process may be used as an add-on for previously existing reversible immortalized cell lines.
doi_str_mv 10.3390/ijms24097738
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10178325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A752424166</galeid><sourcerecordid>A752424166</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3</originalsourceid><addsrcrecordid>eNptkUtLJDEUhYPMMD5mdq6Hgtm4sDWvqqRWoo06gjAgzjqkUjd2mqqkJ0mL7a83ja9WhixuuPe7J5wchPYJPmKsxcduPibKcSsEk1toh3BKJxg34svGfRvtpjTHmDJat9_QNhNE1JzzHXRxNY4hZj24R51d8NUN3ENMrnODy6vK-SrPoJoGn-EhV8FWUxiG6nYGUS9W1ZkLSVvIq-_oq9VDgh8vdQ_9vTi_nf6eXP-5vJqeXk8MlzhPGBgNpmsldLQXTNQdaAmkNJhkuq-5bow2YCkxXFvc2Ja2IOuW95zajgDbQyfPuotlN0JvwOeoB7WIbtRxpYJ26uPEu5m6C_eKYCJkcV8UDl4UYvi3hJTV6JIpprSHsEyKSsLqhtdcFvTXJ3QeltEXf2uKNpi3mL1Td3oA5bwN5WGzFlWnoqacctI0hTr6D1VOD6MzwYN1pf9h4fB5wcSQUgT7ZpJgtQ5ebQZf8J-bH_MGvybNngCWcalY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2812604903</pqid></control><display><type>article</type><title>Immortalization Reversibility in the Context of Cell Therapy Biosafety</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><creator>Sutyagina, Oksana I ; Beilin, Arkadii K ; Vorotelyak, Ekaterina A ; Vasiliev, Andrey V</creator><creatorcontrib>Sutyagina, Oksana I ; Beilin, Arkadii K ; Vorotelyak, Ekaterina A ; Vasiliev, Andrey V</creatorcontrib><description>Immortalization (genetically induced prevention of replicative senescence) is a promising approach to obtain cellular material for cell therapy or for bio-artificial organs aimed at overcoming the problem of donor material shortage. Immortalization is reversed before cells are used in vivo to allow cell differentiation into the mature phenotype and avoid tumorigenic effects of unlimited cell proliferation. However, there is no certainty that the process of de-immortalization is 100% effective and that it does not cause unwanted changes in the cell. In this review, we discuss various approaches to reversible immortalization, emphasizing their advantages and disadvantages in terms of biosafety. We describe the most promising approaches in improving the biosafety of reversibly immortalized cells: CRISPR/Cas9-mediated immortogene insertion, tamoxifen-mediated self-recombination, tools for selection of successfully immortalized cells, using a decellularized extracellular matrix, and ensuring post-transplant safety with the use of suicide genes. The last process may be used as an add-on for previously existing reversible immortalized cell lines.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms24097738</identifier><identifier>PMID: 37175444</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Artificial chromosomes ; Artificial organs ; Biological products ; Biosafety ; Cell cycle ; Cell Differentiation ; Cell division ; Cell Line ; Cell lines ; Cell Proliferation ; Cell therapy ; Containment of Biohazards ; CRISPR ; Differentiation (biology) ; Donor materials ; Extracellular matrix ; Genotype &amp; phenotype ; Human papillomavirus ; Immortalization ; Insulin ; Liu, Timothy ; Phenotypes ; Proteins ; Recombination ; Review ; Safety and security measures ; Senescence ; Stem cells ; Suicide ; Suicide genes ; Telomerase ; Telomerase - metabolism ; Tetracycline ; Tetracyclines ; Tissue engineering</subject><ispartof>International journal of molecular sciences, 2023-04, Vol.24 (9), p.7738</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3</citedby><cites>FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3</cites><orcidid>0000-0001-5405-0212</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2812604903/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2812604903?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37175444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sutyagina, Oksana I</creatorcontrib><creatorcontrib>Beilin, Arkadii K</creatorcontrib><creatorcontrib>Vorotelyak, Ekaterina A</creatorcontrib><creatorcontrib>Vasiliev, Andrey V</creatorcontrib><title>Immortalization Reversibility in the Context of Cell Therapy Biosafety</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Immortalization (genetically induced prevention of replicative senescence) is a promising approach to obtain cellular material for cell therapy or for bio-artificial organs aimed at overcoming the problem of donor material shortage. Immortalization is reversed before cells are used in vivo to allow cell differentiation into the mature phenotype and avoid tumorigenic effects of unlimited cell proliferation. However, there is no certainty that the process of de-immortalization is 100% effective and that it does not cause unwanted changes in the cell. In this review, we discuss various approaches to reversible immortalization, emphasizing their advantages and disadvantages in terms of biosafety. We describe the most promising approaches in improving the biosafety of reversibly immortalized cells: CRISPR/Cas9-mediated immortogene insertion, tamoxifen-mediated self-recombination, tools for selection of successfully immortalized cells, using a decellularized extracellular matrix, and ensuring post-transplant safety with the use of suicide genes. The last process may be used as an add-on for previously existing reversible immortalized cell lines.</description><subject>Artificial chromosomes</subject><subject>Artificial organs</subject><subject>Biological products</subject><subject>Biosafety</subject><subject>Cell cycle</subject><subject>Cell Differentiation</subject><subject>Cell division</subject><subject>Cell Line</subject><subject>Cell lines</subject><subject>Cell Proliferation</subject><subject>Cell therapy</subject><subject>Containment of Biohazards</subject><subject>CRISPR</subject><subject>Differentiation (biology)</subject><subject>Donor materials</subject><subject>Extracellular matrix</subject><subject>Genotype &amp; phenotype</subject><subject>Human papillomavirus</subject><subject>Immortalization</subject><subject>Insulin</subject><subject>Liu, Timothy</subject><subject>Phenotypes</subject><subject>Proteins</subject><subject>Recombination</subject><subject>Review</subject><subject>Safety and security measures</subject><subject>Senescence</subject><subject>Stem cells</subject><subject>Suicide</subject><subject>Suicide genes</subject><subject>Telomerase</subject><subject>Telomerase - metabolism</subject><subject>Tetracycline</subject><subject>Tetracyclines</subject><subject>Tissue engineering</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkUtLJDEUhYPMMD5mdq6Hgtm4sDWvqqRWoo06gjAgzjqkUjd2mqqkJ0mL7a83ja9WhixuuPe7J5wchPYJPmKsxcduPibKcSsEk1toh3BKJxg34svGfRvtpjTHmDJat9_QNhNE1JzzHXRxNY4hZj24R51d8NUN3ENMrnODy6vK-SrPoJoGn-EhV8FWUxiG6nYGUS9W1ZkLSVvIq-_oq9VDgh8vdQ_9vTi_nf6eXP-5vJqeXk8MlzhPGBgNpmsldLQXTNQdaAmkNJhkuq-5bow2YCkxXFvc2Ja2IOuW95zajgDbQyfPuotlN0JvwOeoB7WIbtRxpYJ26uPEu5m6C_eKYCJkcV8UDl4UYvi3hJTV6JIpprSHsEyKSsLqhtdcFvTXJ3QeltEXf2uKNpi3mL1Td3oA5bwN5WGzFlWnoqacctI0hTr6D1VOD6MzwYN1pf9h4fB5wcSQUgT7ZpJgtQ5ebQZf8J-bH_MGvybNngCWcalY</recordid><startdate>20230423</startdate><enddate>20230423</enddate><creator>Sutyagina, Oksana I</creator><creator>Beilin, Arkadii K</creator><creator>Vorotelyak, Ekaterina A</creator><creator>Vasiliev, Andrey V</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5405-0212</orcidid></search><sort><creationdate>20230423</creationdate><title>Immortalization Reversibility in the Context of Cell Therapy Biosafety</title><author>Sutyagina, Oksana I ; Beilin, Arkadii K ; Vorotelyak, Ekaterina A ; Vasiliev, Andrey V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Artificial chromosomes</topic><topic>Artificial organs</topic><topic>Biological products</topic><topic>Biosafety</topic><topic>Cell cycle</topic><topic>Cell Differentiation</topic><topic>Cell division</topic><topic>Cell Line</topic><topic>Cell lines</topic><topic>Cell Proliferation</topic><topic>Cell therapy</topic><topic>Containment of Biohazards</topic><topic>CRISPR</topic><topic>Differentiation (biology)</topic><topic>Donor materials</topic><topic>Extracellular matrix</topic><topic>Genotype &amp; phenotype</topic><topic>Human papillomavirus</topic><topic>Immortalization</topic><topic>Insulin</topic><topic>Liu, Timothy</topic><topic>Phenotypes</topic><topic>Proteins</topic><topic>Recombination</topic><topic>Review</topic><topic>Safety and security measures</topic><topic>Senescence</topic><topic>Stem cells</topic><topic>Suicide</topic><topic>Suicide genes</topic><topic>Telomerase</topic><topic>Telomerase - metabolism</topic><topic>Tetracycline</topic><topic>Tetracyclines</topic><topic>Tissue engineering</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sutyagina, Oksana I</creatorcontrib><creatorcontrib>Beilin, Arkadii K</creatorcontrib><creatorcontrib>Vorotelyak, Ekaterina A</creatorcontrib><creatorcontrib>Vasiliev, Andrey V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sutyagina, Oksana I</au><au>Beilin, Arkadii K</au><au>Vorotelyak, Ekaterina A</au><au>Vasiliev, Andrey V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immortalization Reversibility in the Context of Cell Therapy Biosafety</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2023-04-23</date><risdate>2023</risdate><volume>24</volume><issue>9</issue><spage>7738</spage><pages>7738-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Immortalization (genetically induced prevention of replicative senescence) is a promising approach to obtain cellular material for cell therapy or for bio-artificial organs aimed at overcoming the problem of donor material shortage. Immortalization is reversed before cells are used in vivo to allow cell differentiation into the mature phenotype and avoid tumorigenic effects of unlimited cell proliferation. However, there is no certainty that the process of de-immortalization is 100% effective and that it does not cause unwanted changes in the cell. In this review, we discuss various approaches to reversible immortalization, emphasizing their advantages and disadvantages in terms of biosafety. We describe the most promising approaches in improving the biosafety of reversibly immortalized cells: CRISPR/Cas9-mediated immortogene insertion, tamoxifen-mediated self-recombination, tools for selection of successfully immortalized cells, using a decellularized extracellular matrix, and ensuring post-transplant safety with the use of suicide genes. The last process may be used as an add-on for previously existing reversible immortalized cell lines.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37175444</pmid><doi>10.3390/ijms24097738</doi><orcidid>https://orcid.org/0000-0001-5405-0212</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2023-04, Vol.24 (9), p.7738
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10178325
source PubMed Central (Open Access); Publicly Available Content Database
subjects Artificial chromosomes
Artificial organs
Biological products
Biosafety
Cell cycle
Cell Differentiation
Cell division
Cell Line
Cell lines
Cell Proliferation
Cell therapy
Containment of Biohazards
CRISPR
Differentiation (biology)
Donor materials
Extracellular matrix
Genotype & phenotype
Human papillomavirus
Immortalization
Insulin
Liu, Timothy
Phenotypes
Proteins
Recombination
Review
Safety and security measures
Senescence
Stem cells
Suicide
Suicide genes
Telomerase
Telomerase - metabolism
Tetracycline
Tetracyclines
Tissue engineering
title Immortalization Reversibility in the Context of Cell Therapy Biosafety
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A49%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immortalization%20Reversibility%20in%20the%20Context%20of%20Cell%20Therapy%20Biosafety&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Sutyagina,%20Oksana%20I&rft.date=2023-04-23&rft.volume=24&rft.issue=9&rft.spage=7738&rft.pages=7738-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms24097738&rft_dat=%3Cgale_pubme%3EA752424166%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c480t-3ecaecb98eb2d7375bea8e1b98383ad54a6cacef21c4af06f929e8594d42fb1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2812604903&rft_id=info:pmid/37175444&rft_galeid=A752424166&rfr_iscdi=true